Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tremelimumab: First Approval
Susan J. Keam
Drugs (2022) Vol. 83, Iss. 1, pp. 93-102
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 267
Immunosurveillance in clinical cancer management
Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 2, pp. 187-202
Open Access | Times Cited: 62
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
Lingjiao Meng, Haotian Wu, Jiaxiang Wu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 57
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Ke Xin Lin, Alexandra C. Istl, Douglas Quan, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 3875-3893
Open Access | Times Cited: 51
New insight in immunotherapy and combine therapy in colorectal cancer
Kai Ji, Hang Jia, Zixuan Liu, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 2
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes
Antonio Farina, Macarena Villagrán‐García, Alberto Vogrig, et al.
The Lancet Neurology (2023) Vol. 23, Iss. 1, pp. 81-94
Open Access | Times Cited: 39
Therapeutic Antibodies in Medicine
Prerna Sharma, Rahul V. Joshi, Robert C. Pritchard, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6438-6438
Open Access | Times Cited: 29
Lipid-based nanosystems: the next generation of cancer immune therapy
Ziyun Cheng, Seth‐Frerich Fobian, Elena Gurrieri, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges
Shunzhen Zheng, Siew Wee Chan, Fei Liu, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1582-1582
Open Access | Times Cited: 12
New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication
Sha Qin, Bin Xie, Qingyi Wang, et al.
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 12
Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b)
Lixin Zhou, Jiamei Yang, Kuojun Zhang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 816-837
Closed Access | Times Cited: 9
Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment
Xiaoxue Lang, Xiangtao Wang, Meihua Han, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 4533-4568
Open Access | Times Cited: 9
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Advancements in the application of ablative therapy and its combination with immunotherapy in anti-cancer therapy
Luhong Wang, Yiyi Jiang, Chaoyue Sun, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 2, pp. 189285-189285
Closed Access | Times Cited: 1
Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy
Eman M. Abdo, Imad Ajib, Jason El Mounzer, et al.
Inflammation Research (2025) Vol. 74, Iss. 1
Closed Access | Times Cited: 1
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
Nicole L. France, Hannah A. Blair
Targeted Oncology (2024) Vol. 19, Iss. 1, pp. 115-123
Open Access | Times Cited: 7
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Samantha M. Ruff, Ashish Manne, Jordan M. Cloyd, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5863-5875
Open Access | Times Cited: 13
Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade
Eun‐Ji Lee, Young Soo Kim, Ji Hye Kim, et al.
Phytomedicine (2024) Vol. 125, pp. 155370-155370
Open Access | Times Cited: 5
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors
Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9659-9659
Open Access | Times Cited: 5
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging
Brian Effer, Isabela Perez, Daniel Ulloa, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 2086-2086
Open Access | Times Cited: 12
Antitumor effect of plant-produced anti-CTLA-4 monoclonal antibody in a murine model of colon cancer
Christine Joy I. Bulaon, Narach Khorattanakulchai, Kaewta Rattanapisit, et al.
Frontiers in Plant Science (2023) Vol. 14
Open Access | Times Cited: 12
The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
Lidy Vannessa Mejía-Guarnizo, Paula Stefany Monroy-Camacho, Andrés David Turizo-Smith, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review
Carlo Augusto Mallio, Caterina Bernetti, Laura Cea, et al.
Current Oncology (2023) Vol. 30, Iss. 5, pp. 4700-4723
Open Access | Times Cited: 11
Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy
Haoyuan Zhou, Cui‐Yun Yu, Hua Wei
International Journal of Pharmaceutics (2024) Vol. 652, pp. 123818-123818
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top